Kymera Therapeutics, Inc. has commenced an underwritten public offering of $200.0 million of shares of its common stock and pre-funded warrants to purchase shares of its common stock. The net proceeds from the offering will be used to advance its pipeline of preclinical and clinical degrader programs and for working capital and other general corporate purposes.
Company Information
Company
Kymera Therapeutics
Location
Watertown, Massachusetts, United States
About
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.
WatertownBiotechnologyTherapeuticsPharmaceuticalBiopharma